EU Approves Daiichi Sankyo And AstraZeneca's Datroway For First-Line Metastatic TNBC, Showing 5.0 Month Overall Survival Improvement Over Chemotherapy In TROPION-Breast02 Trial
AstraZeneca PLC
دايتشي سانكيو ADR
AstraZeneca PLC AZN | 0.00 | |
DAIICHI SANKYO COMPANY LIMITED DSNKY | 0.00 |
- Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival
- Datroway now approved for two breast cancer indications in the EU